The global connected drug delivery devices market size was valued at USD 3.73 billion in 2025 and is projected to grow from USD 4.35 billion in 2026 to USD 14.96 billion by 2034, registering a CAGR of 16.69% during the forecast period (2026–2034). North America dominated the connected drug delivery devices market with a share of 32.41% in 2025.
Connected drug delivery devices are smart medical devices that combine drug administration with digital connectivity, sensors, and data-monitoring technologies to support accurate medication delivery and treatment management. Connected drug delivery devices are generally tracked under HSN Code 9018 (instruments and appliances used in medical, surgical, dental, or veterinary sciences) and SIC Code 3841 (Surgical and Medical Instruments and Apparatus).
The connected drug delivery devices market demand is driven by the need for medication adherence, the adoption of digital healthcare technologies, and preference for remote treatment monitoring and personalized drug administration. The adoption of connected inhalers, smart insulin pens, connected autoinjectors, smart injection devices, and connected infusion systems contributes to connected drug delivery devices market growth.
By Product
By Device Type
By Application
By End User
Download a Free Sample To learn more about this report,
Integration of IoT Connectivity with Drug Delivery Systems
The connected drug delivery devices market analysis shows shift towards the integration of IoT connectivity with drug delivery systems for real-time device and medication monitoring. Connected devices can transmit information such as dosage, administration time, device status, and usage patterns to mobile applications or digital healthcare platforms. This integration is improving data visibility and enabling healthcare professionals to monitor treatment information remotely.
Shift toward Connected Autoinjectors and Smart Pens
The connected drug delivery devices market is witnessing growth in connected autoinjectors and smart insulin pens equipped with digital sensors, connectivity features, and dose-tracking capabilities. These devices can record injection timing, dosage information, and device usage while transferring data to connected applications. The integration of digital features is improving medication tracking and supporting more structured management of injectable therapies.
Supply chain disruptions are expected to have a high impact on the connected drug delivery devices market share due to dependence on sensors, microcontrollers, semiconductors, batteries, connectivity modules, electronic components, and specialized medical-device manufacturing and distribution networks. The market is expected to follow a U-shaped recovery, as shortages of electronic components, sensor production delays, higher component costs, and medical-device logistics constraints can prolong supply interruptions before manufacturing and inventory levels stabilize. The market is expected to grow at a CAGR of 16.69%, but supply chain constraints could approximately lower this by 1.5 percentage points, resulting in short-term growth of around 15.19%. As supply conditions normalize through improved availability of semiconductors and sensors, stabilized component costs, expanded manufacturing capacity, and smoother medical-device logistics, connected drug delivery devices market growth is expected to gradually return to 16.69%.
The connected drug delivery devices market forecasts strategic investment activity driven by smart drug delivery platform development, wearable injector expansion, medication adherence monitoring, connected device integration, digital health capabilities, and manufacturing scale-up.
Key Investments and Funding Activities in Connected Drug Delivery Devices Market, 2025–2026
ViCentra
USD 98 Million
In January 2026, ViCentra closed a USD 13 million extension to its Series D financing, bringing the total Series D funding to USD 98 million. The funding is supporting manufacturing scale-up, commercial expansion, and planned U.S. market access for its Kaleido insulin patch pump, a connected drug delivery device.
Daré Bioscience
USD 4 Million
In October 2025, Daré Bioscience received a USD 4 million non-dilutive funding installment under a grant agreement supporting development of its DARE-IDDS intelligent drug delivery system. The installment brought total funding received under the commitment to approximately USD 41.8 million, supporting development of a programmable drug delivery device.
Need for Medication Adherence Monitoring and Demand for Real-Time Dose Tracking Drives Market
The need for medication adherence monitoring is driving demand for connected devices that help patients follow prescribed treatment schedules. Digital drug delivery systems can record dosing activity and provide reminders when scheduled doses are missed. Connected data can also help healthcare providers monitor treatment use and identify adherence gaps. This focus on better medication management is supporting adoption of connected drug delivery devices.
The demand for real-time dose tracking is increasing the use of connected drug delivery devices that capture and share dosing information. Integration with remote patient monitoring (RPM) systems allows healthcare providers to receive medication-use data without requiring frequent in-person visits. Real-time information can support timely follow-up and improve visibility into treatment patterns. This growing need for connected monitoring supports connected drug delivery devices market growth.
Difficulty in Maintaining Patient Engagement and Inconsistent Data Synchronization Across Devices Restrains Market Expansion
Difficulty in maintaining patient engagement can limit the effective use of connected drug delivery devices over time. Patients may stop using companion apps, ignore reminders, or lose interest in tracking their medication after initial adoption. Low engagement can reduce the effectiveness of medication adherence monitoring and remote patient monitoring (RPM) features. This can limit the long-term value of digital drug delivery solutions and restrain market growth.
Inconsistent data synchronization can affect the reliability of information collected from connected drug delivery devices. Delays or errors in transferring dose records between devices, mobile applications, and cloud platforms can result in incomplete or inaccurate medication data. Such issues can reduce the usefulness of real-time dose tracking for patients and healthcare providers.
Expansion of Connected Drug Delivery in Chronic Disease Management and Integration with Internet of Medical Things (IoMT) Offers Growth Opportunities
The need for long-term treatment is creating opportunities for connected drug delivery device manufacturers to serve patients managing diabetes, asthma, and cardiovascular conditions. Digital drug delivery devices can support medication adherence through dose tracking, reminders, and connected monitoring features.
The growing adoption of the Internet of Medical Things (IoMT) is creating opportunities for connected drug delivery device manufacturers to link smart injectors, inhalers, pumps, and other devices with healthcare networks. Companies such as Medtronic and Becton, Dickinson and Company can benefit by developing IoMT-enabled drug delivery solutions, creating revenue through connected devices, software platforms, and data-enabled services.
Limited Standardized Outcomes and Complex Interoperability with Healthcare Systems Hinders Market Growth
Manufacturers face difficulties generating robust evidence that connected drug delivery devices improve medication adherence, clinical outcomes, or healthcare efficiency. Limited standardized outcome measures and economic evidence can make payer and provider acceptance more difficult, increasing evidence-generation costs and slowing commercial expansion.
Connected drug delivery devices must exchange data with EHRs, healthcare apps, and other digital systems, but differences in data standards and system architectures can require customized interfaces and additional testing. These integration requirements increase development and implementation costs, delay deployment, and make expansion across healthcare systems more complex.
The standalone components & software segment is expected to grow at a CAGR of 15.21% during the forecast period, fueled by the availability of connectivity modules, sensors, and digital platforms that add tracking and monitoring capabilities to existing drug delivery systems.
The integrated devices segment is expected to grow at a CAGR of 17.58% during the forecast period, driven by the incorporation of connectivity, dose tracking, and digital monitoring features directly into drug delivery devices.
Request Customizationto receive a tailored report.
The pen and autoinjectors segment accounted for a share of 28.63% in 2025 due to their convenient and patient-friendly design for self-administration of injectable medicines. Connected pens and autoinjectors can record dose timing and quantity while supporting reminders and data sharing.
The wearable injectors segment is expected to grow at a CAGR of 18.46% during the forecast period, supported by demand for convenient administration of larger-volume or longer-duration injectable therapies.
The diabetes segment accounted for a share of 38.62% in 2025, fueled by the widespread use of connected insulin pens and other digital drug delivery technologies for insulin administration. Dose tracking, reminders, dose calculations, and connectivity with glucose monitoring platforms support more structured diabetes management.
The autoimmune diseases segment is expected to grow at a CAGR of 17.06% during the forecast period, driven by the use of self-administered injectable therapies for conditions requiring regular dosing.
The homecare settings segment accounted for a share of 48.36% in 2025 due to the growing use of self-administered injectable therapies and connected devices outside clinical facilities. Digital dose tracking, reminders, and data transmission can help patients and healthcare providers monitor medication use remotely.
The specialty care centers segment is expected to grow at a CAGR of 15.94% during the forecast period, propelled by the use of connected delivery devices for patients receiving specialized and long-term injectable therapies.
Speak to an Analystto discuss market opportunities.
North America: Market Dominance Supported by Digital Drug Delivery and Medication Adherence
The North America connected drug delivery devices market accounted for the regional share of 32.41%, supported by strong adoption of digital drug delivery technologies, connected insulin pens, smart inhalers, and remote patient monitoring solutions.
The US connected drug delivery devices market is driven by the growing integration of connected insulin pens and digital medication management into diabetes care. The American Diabetes Association’s Standards of Care recognize connected insulin pens as devices that can record or transmit insulin-dose data and support real-time dosing and clinician review, strengthening the role of connected drug delivery in diabetes management.
The Canada connected drug delivery devices market is shaped by growing research and development around medication adherence technologies. Researchers from the University of Waterloo, Canadian Pharmacists Association, University of Toronto, McMaster University, and National Research Council Canada developed a taxonomy of medication adherence technologies, covering digital tools designed to monitor and support medication use, demonstrating the growing Canadian focus on technology-enabled medication adherence.
Unlock Regional Insightsto access country-level data, & regional trends.
Asia Pacific: Fastest Growth Driven by Smart Drug Delivery Technologies and Digital Therapeutics
The Asia Pacific connected drug delivery devices market is expected to grow at a CAGR of 18.69% during the forecast period, showcasing the fastest-growing regional market.
The India connected drug delivery devices market is driven by growing development of smart injection technologies and digital health platforms. Wockhardt Research Centre has developed a smart insulin pen system with the W-SMART app, linking insulin dose management with digital connectivity and supporting electronic recording of injection information.
The China connected drug delivery devices market is supported by the adoption of IoT-enabled electronic injection devices for chronic disease management. Xiamen Amoytop Biotech’s Yushida smart injection pen connects with a patient application through Bluetooth, records injection and treatment information, and uses cloud-based services for monitoring and data management.
The Japan connected drug delivery devices market is fueled by the integration of digital therapeutics (DTx) with digitally connected healthcare technologies. Shionogi is developing a DTx distribution platform with NTT DATA and other partners to support the wider use of prescription digital therapeutics, creating an ecosystem for software-based treatment and connected patient management.
Europe: Market Expansion Fueled by Expansion of Wearable Drug Delivery and Focus on Chronic Disease Management
The Europe connected drug delivery devices market is expected to grow at a CAGR of 15.94% during the forecast period, fueled by the adoption of digital drug delivery, connected wearable systems, and remote medication management for chronic diseases.
The UK connected drug delivery devices market is shaped by the NHS adoption of wearable insulin delivery systems, with the national framework covering connected combinations such as Omnipod 5, YpsoPump, Tandem T X2, and Medtronic MiniMed 780G with continuous glucose monitoring and automated insulin-delivery algorithms.
Germany’s 2026 digital-health legislation plans further expansion of the electronic patient record, digital medication processes, and interoperable healthcare systems, with electronic prescriptions and connected digital services being expanded through 2027–2029, creating a stronger infrastructure for connected drug-delivery technologies.
Latin America: Market Shaped by Smartphone-based Delivery and Focus on Continuous Remote Medication
The Latin America connected drug delivery devices market is expected to grow at a CAGR of 16.21%, during the forecast period. In Brazil, the OxyKids digital health platform is being evaluated for children with asthma, using smartphone-based records of inhaler use to monitor medication adherence and asthma control, demonstrating the application of connected digital tools in respiratory drug delivery. In Mexico, the growing use of digital asthma management platforms and remote medication monitoring is supporting greater integration of connected technologies with inhaled therapies, enabling patients and healthcare professionals to track medication use and identify adherence gaps.
Middle East & Africa: Market Expansion Led by Adoption of IoT-enabled Predictive Patient Monitoring Platforms
The Middle East & Africa connected drug delivery devices market is expected to grow at a CAGR of 15.47%, during the forecast period. In the UAE, Emirates Health Services uses IoT-enabled predictive patient monitoring to track vital signs and real-time health data, supporting remote clinical review and connected healthcare. In South Africa, the Adherence Support Coalition to End TB (ASCENT) trial implemented digital adherence technologies across clinics in Gauteng and North West provinces, including smart pillboxes that recorded medication-taking events and transmitted adherence data to a digital platform for healthcare-worker review.
The connected drug delivery devices market competitive landscape is highly fragmented, with established medical device manufacturers, drug delivery technology companies, pharmaceutical delivery solution companies, and specialty device manufacturers. Key players such as Medtronic, Insulet Corporation, BD, West Pharmaceutical Services, Inc., and AptarGroup, Inc. are estimated to account for 30–35% of the global connected drug delivery devices market share.
Established players compete mainly through digital drug delivery capabilities, device connectivity, medication adherence monitoring, device reliability, and patient-centric design. Emerging and regional players in the connected drug delivery devices market ecosystem focus on personalized delivery solutions, local distribution, and application-specific connected devices.
May 2026: ViCentra commercially launched its new smartphone-controlled Kaleido automated insulin delivery patch pump system, integrating Diabeloop’s DBLG2 algorithm and Dexcom G7 continuous glucose monitoring for connected insulin delivery.
January 2026: BD highlighted its Libertas wearable injector and other large-volume drug delivery technologies at Pharmapack 2026, targeting subcutaneous administration of high-dose biologics and supporting the shift from intravenous to at-home delivery.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanshee Bhapkar is a healthcare research professional with 4+ years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.
Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.
Europe Diabetes Devices Market Size & Trends by 2034
Antimicrobial Regenerative Wound Matrix Market Size, Share, 2034
Cardiac Resynchronization Therapy (CRT) Market Size, Share, 2034
Automated Microbial Identification Market Size, Share, Growth, 2034
Microsutures Market Size, Share, Growth, Analysis, Report, 2034
Capnography Device Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com